Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.010
-0.110 (-5.19%)
At close: Nov 28, 2025, 1:00 PM EST
2.003
-0.007 (-0.34%)
After-hours: Nov 28, 2025, 4:57 PM EST
Adagene Revenue
Adagene had revenue of $103.20K in the twelve months ending June 30, 2025, down -87.35% year-over-year. In the year 2024, Adagene had annual revenue of $103.20K, down -99.43%.
Revenue (ttm)
$103.20K
Revenue Growth
-87.35%
P/S Ratio
917.93
Revenue / Employee
$748
Employees
138
Market Cap
94.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADAG News
- 15 days ago - Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire
- 4 weeks ago - Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 2 months ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
- 3 months ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
- 3 months ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire
- 3 months ago - Adagene to Participate in Two Investor Conferences in September - GlobeNewsWire
- 3 months ago - Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewsWire